贝达药业：对于肺癌治疗领域的持续用药品种，目前有MCLA-129、CFT8919项目正在临床研究中

Core Viewpoint - The company is actively developing targeted therapies for lung cancer, focusing on two clinical projects, MCLA-129 and CFT8919, while maintaining a dynamic evaluation mechanism for project value and resource allocation [1]. Group 1: Clinical Research Projects - The company has two ongoing clinical research projects in the lung cancer treatment area: MCLA-129 and CFT8919 [1]. - The company aims to concentrate resources on these projects to expedite the development of new drug candidates [1]. Group 2: Project Evaluation and Resource Management - The company has established a mature evaluation mechanism to dynamically assess the value of its projects [1]. - This mechanism allows the company to make timely adjustments and ensure efficient utilization of research and development resources [1].